The Ministry of External Affairs announced on Thursday that it will host the inaugural edition of the Technology Dialogue ...

As the US remains the top market for the Indian pharmaceutical industry, experts in India are now expecting opportunities for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Kiran Mazumdar-Shaw, Chairperson of major drugmaker Biocon Ltd., urged the government to eliminate tax on drugs for cancer treatment and for chronic and rare diseases, ahead of the budget 2025 ...

Hence, we recommend buying Reliance Industries around Rs 1,290. Biocon is reflecting strong volumes over the past week, indicating growing investor interest. The stock is approaching a critical ...

Divis Labs has been an outperformer in the pharma pack so far in this series, as most of the pharma stocks have corrected in the January series, apart from a few like Divis Labs and Biocon.

Biocon Ltd. key Products/Revenue Segments include Bio Pharmaceuticals, Other Operating Revenue, Waste and Sale of services for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company ...

Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks to make biologic therapies affordable, accessible and available to all. He ...

Bajaj Finserv Ltd., Biocon Ltd., and Hindustan Copper Ltd. have buy recommendations from analysts on Tuesday. Kushal Gandhi, technical analyst at StoxBox, Aditya Agarwala, head of research and ...